Adalimumab, infliximab equally effective in treating Crohn's — 4 insights

A study, published in Alimentary Pharmacology and Therapeutics, examined the effectiveness of adalimumab and infliximab in treating Crohn's disease patients.

Study authors examined 827 Danish adults with Crohn's disease. Approximately 315 used adalimumab and 512 were treated with infliximab. Median disease duration was four years, and researchers followed up with the patients 2.3 years after starting the biological therapy. Researchers used Cox regression models to compare rates of all-cause hospitalization.

Here's what they found:

1. After starting the therapies, researchers observed no significant difference in Crohn's disease hospitalization rates between the two therapy groups.

2. Adalimumab-treated patients had a lower rate of all-cause hospitalization than infliximab-treated patients.

3. There were no differences in serious infection rates between the two groups.

4. Results were stable in patients treated with biological monotherapy or when used in combination with immunomodulators.

Researchers concluded, "In this population-based, propensity score matched, real-life cohort study using administrative claims, there was no significant difference in effectiveness and safety of adalimumab and infliximab in biologic-naïve patients with CD."

More articles on gastroenterology: 
GI leader to know: Dr. Brian Blair of the Kennedy Health Alliance
Allergan director acquires 3k+ shares — CNBC analyst calls company 'anti-bitcoin'
Vizinet awards Karl Storz innovative technology designation — 4 insights

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months